Physician profile
Mark J Kellum
NPI 1881665859
$2,177.79
in general payments reported to CMS, 2019-2025
24 companies · $606 in 2025
The $606 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $108 · 2021: $375 · 2022: $383 · 2023: $150 · 2024: $351 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,008.18 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $457.61 | 2023-2025 | Veozah |
| Abbvie INC. | $404.93 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $163.78 | 2022-2025 | |
| Aspira Women'S Health INC | $157.41 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $140.61 | 2019-2022 | |
| Organon LLC | $127.56 | 2021-2025 | Jada System, Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $80.10 | 2019-2024 | |
| Biogen, INC. | $70.02 | 2024 | Zurzuvae |
| Millicent US INC | $68.29 | 2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $60.67 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $53.81 | 2019-2024 | Injectafer |
| Amag Pharmaceuticals, INC. | $47.56 | 2019 | |
| Lupin INC. | $47.53 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.87 | 2022 | |
| Hologic Sales and Service, LLC | $39.80 | 2023-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.84 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $31.51 | 2019-2022 | |
| Amgen INC. | $30.69 | 2025 | Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $30.11 | 2021-2022 | |
| Ardelyx, INC. | $29.03 | 2025 | Ibsrela |
| Avion Pharmaceuticals | $24.39 | 2019-2020 | |
| Therapeuticsmd, INC. | $15.09 | 2021 | |
| Shield Therapeutics INC | $13.17 | 2023 | Accrufer |
| Coopersurgical, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.